🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Switzerland / NCT04130789
Recruiting Observational

Personalized Swiss Sepsis Study

NCT04130789 · tracked via the Priya Life Science Switzerland tracker
Phase
Observational
Started
2019-11-15
Last updated
2025-03-05

Condition(s) studied

Sepsis

Investigational drug(s) / intervention(s)

compare data patterns by data-driven algorithms to determine sepsiscompare data patterns by data-driven algorithms to predict sepsis-related mortality

compare data patterns by data-driven algorithms to determine sepsis: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis

compare data patterns by data-driven algorithms to predict sepsis-related mortality: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality

Study summary

This multi-center study is to focus on patients with sepsis in Intensive Care Units (ICUs) in order to better understand the complex host-pathogen interaction and clinical heterogeneity associated with sepsis. Understanding this heterogeneity may allow the development of novel diagnostic approaches. Data from patients will be analyzed using state-of-the art analytical algorithms for biomarker discovery including machine learning and multidimensional mathematical modelling to explore the large datasets generated. In order to discover digital biomarkers for the study endpoints a case-control study design will be used to compare data patterns from patients with sepsis (cases) and those without sepsis (controls).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients admitted to an ICU on a Swiss University Hospital. * Patients expected to stay at least 24h on the ICU Inclusion Criteria (cases) * Present at admission to ICU or subsequent development of sepsis 3.0 criteria Inclusion Criteria (controls) * Patients not fulfilling sepsis definition during the ICU stay Exclusion Criteria: * Decline of general consent or any other negative statement against using data for research. * Patients with a clear elective stay on the ICUs.

Primary outcome measure(s)

Trial sites (16)

FacilityCityRegionStatus
Clinical Microbiology, University Hospital Basel Basel Switzerland Recruiting
Infectious Diseases and Hospital Epidemiology, University Hospital Basel Basel Switzerland Recruiting
Medical Intensive Care Unit; University Hospital Basel Basel Switzerland Recruiting
Surgical Intensive Care Unit, University Hospital Basel Basel Switzerland Recruiting
Institute for Infectious Diseases, University of Bern Bern Switzerland Recruiting
Division Infectious Diseases, University Hospital Bern Bern Switzerland Recruiting
Intensive Care Medicine, University Hospital Bern Bern Switzerland Recruiting
Division Bacteriology Laboratory, University Hospital Geneva Geneva Switzerland Recruiting
Division Infectious Diseases, University Hospital Geneva Geneva Switzerland Recruiting
Intensive Care Medicine, University Hospital Geneva Geneva Switzerland Recruiting
Division Intensive Care Medicine, University Hospital Lausanne Lausanne Switzerland Recruiting
Institute of Microbiology, University Hospital Lausanne Lausanne Switzerland Recruiting
Service Infectious Diseases, University Hospital Lausanne Lausanne Switzerland Recruiting
Institute for Medical Microbiology, University Hospital Zurich Zurich Switzerland Not Yet Recruiting
Division Infectious Diseases, University Hospital Zurich Zurich Switzerland Not Yet Recruiting
Institute for Intensive Medicine, University Hospital Zurich Zurich Switzerland Not Yet Recruiting

More University Hospital, Basel, Switzerland trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04130789 on ClinicalTrials.gov ↗ ← All trials in Switzerland